NCT00108797 - Trial of NovoSeven® in Haemophilia - Joint Bleeds | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions

Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors

Interventions

DRUG

eptacog alfa (activated)

DRUG

Feiba VH

Trial Locations (20)

17033

Novo Nordisk Investigational Site, Hershey

19104

Novo Nordisk Investigational Site, Philadelphia

45229

Novo Nordisk Investigational Site, Cincinnati

46260

Novo Nordisk Investigational Site, Indianapolis

48201

Novo Nordisk Investigational Site, Detroit

52242

Novo Nordisk Investigational Site, Iowa City

55404

Novo Nordisk Investigational Site, Minneapolis

60612

Novo Nordisk Investigational Site, Chicago

70112

Novo Nordisk Investigational Site, New Orleans

72202

Novo Nordisk Investigational Site, Little Rock

77030

Novo Nordisk Investigational Site, Houston

80010

Novo Nordisk Investigational Site, Aurora

90027

Novo Nordisk Investigational Site, Los Angeles

94704

Novo Nordisk Investigational Site, Berkeley

02115

Novo Nordisk Investigational Site, Boston

08903

Novo Nordisk Investigational Site, New Brunswick

07112

Novo Nordisk Investigational Site, Newark

10029-6574

Novo Nordisk Investigational Site, New York

27599-7220

Novo Nordisk Investigational Site, Chapel Hill

19134-1095

Novo Nordisk Investigational Site, Philadelphia